-
Gilead Soothes Price War Worry With Q1 Results
Friday, May 1, 2015 - 12:29pm | 535Read More...Gilead Sciences, Inc. (NASDAQ: GILD) gained more than 3 percent early in Friday's session on earnings and news that first quarter revenue from its hepatitis C treatments rose sequentially by 19 percent to well ahead of Wall Street's estimates. Shares traded recently at $105.48, up 5...
-
Is Gilead Sciences About To Buy Vertex For $45 Billion?
Thursday, April 30, 2015 - 11:57am | 498Read More...Gilead Sciences, Inc. (NASDAQ: GILD) has been rolling in the money since the release of its hepatitis C drug duo, Sovaldi and Harvoni. Now investors are wondering how Gilead will put its pile of cash to work. In its Q4 earnings report, Gilead announced that its cash position had increased from...
-
What's Wall Street Been Saying About Gilead Lately?
Wednesday, April 29, 2015 - 12:34pm | 588Read More...Gilead Sciences, Inc. (NASDAQ: GILD) is scheduled to release its first quarter results on Thursday after market close. The Estimize consensus earnings per share estimate (based on 137 estimates) is $2.48 on revenue of $7.049 billion. This compares to the Wall Street Consensus earnings per...
-
This Data Offers Insight Into Gilead Sales
Wednesday, April 8, 2015 - 12:44pm | 587Read More...Gilead Sciences, Inc. (NASDAQ: GILD) received new data from IMS Health about the breakdown of its drug prescriptions. Gilead is most known for its hepatitis C medications, Harvoni and Sovaldi. IMS prescription data breaks down how many people are receiving which drug prescriptions in more than...
-
Gilead Shares Tumble On Drug Warning; Baird Says Buy
Monday, March 23, 2015 - 8:33am | 208Read More...Two drugs that account for more than half of Gilead Sciences, Inc.'s (NASDAQ: GILD) sales may also cause abnormally slow heartbeats, according to a warning sent by the company on Friday. Shares of Gilead were lower by more than 3 percent in pre-market trading. According to the warning,...
-
A Look At 3 Biotech Stocks With Upside Potential
Monday, January 12, 2015 - 5:25pm | 459Read More...Kite Pharma Inc (NASDAQ: KITE) continued its winning streak, up another 4 percent Monday. Although the stock more than tripled in price over the past six months, analysts still see upside left. Mizuho Securities initiated coverage on the stock last Friday, with a Buy rating and a $90 price target...
-
UPDATE: Barclays Initiates Coverage On Gilead Sciences, 'Should Remain Ahead Of Its Peers'
Tuesday, January 6, 2015 - 10:08am | 207Read More...Geoffrey Meacham of Barclays initiated coverage of Gilead Sciences, Inc. (NASDAQ: GILD) on Tuesday with an Overweight rating and $125 price target. According to Meacham, Gilead Sciences' will likely see “dramatic growth” in hepatitis C that should drive upside in 2015 and beyond. Specifically, the...
